Vitamin K2
Vitamin K2 switches on the proteins that steer calcium into bone and keep it out of artery walls, and that mechanism is well established. What isn't established is that taking it prevents heart attacks, fractures or early death: the trials measure scans and markers, not events, and they are split between positive and null.
If you take vitamin D3 or a calcium supplement, adding 90–180 µg a day of the MK-7 form of K2 is a cheap, very safe and reasonable pairing. Take it with a meal that contains some fat. If you take warfarin or another vitamin-K-antagonist blood thinner, don't start it without your prescriber.
What K2 does: it decides where calcium goes
Vitamin K comes in two families. K1 (phylloquinone), from leafy greens, is what the liver uses to make clotting factors, and ordinary diets supply plenty of it. K2 (the menaquinones), from fermented foods and animal fats, reaches tissues outside the liver, the blood vessels and the skeleton, and is thin in Western diets.
Vitamin K is needed for one chemical step, carboxylation, that switches on proteins which then bind calcium. Two carry the whole longevity argument:
- Osteocalcin, made by bone cells, pulls calcium into bone.
- Matrix Gla protein (MGP), made in artery walls, sweeps calcium out of soft tissue and is the most potent natural brake on calcification of the blood vessels known.
When vitamin K status is low, both proteins circulate switched off. You can absorb calcium perfectly well (vitamin D handles that) and still lack the machinery to route it, the setup behind the so-called "calcium paradox", where the same person loses calcium from bone while depositing it in arteries.[1] The switched-off form of MGP, measured in blood as dp-ucMGP, predicts arterial stiffness and cardiovascular events. The mechanism and the biomarker's predictive value are strong; whether moving the biomarker changes outcomes is the open question the trials below wrestle with.[2]
That is why K2 sits alongside calcium and vitamin D: it doesn't add calcium, it routes it.
Choose MK-7, not MK-4
The two K2 forms worth knowing behave very differently. MK-4, like K1, is cleared from the blood within about an hour or two; MK-7 stays for several days.[3] A small daily MK-7 dose keeps the proteins switched on in a way that food-level MK-4 cannot, because MK-4 is cleared within hours and absorbed poorly at those doses.[4] The better-studied trials use MK-7.
MK-4 is the form behind almost all the fracture trials, at about 45 mg a day, roughly 250 times a supplement capsule, as a Japanese prescription osteoporosis drug. Those trials don't bear the weight placed on them: the meta-analysis that reported large fracture reductions included trials from a research group whose work has since faced serious integrity concerns, and now carries a formal correction.[5] [6] The one large trial free of those concerns missed its main goal and had more adverse events on the drug.[7]
Arteries: the scans move a little; fewer heart attacks haven't been shown
The population data are encouraging but observational. In the Rotterdam Study, which followed 4,807 adults for up to a decade, those in the highest third of dietary K2 intake had roughly half the coronary heart disease mortality and severe aortic calcification of the lowest third, while K1 intake showed no association at all.[8] People who eat more K2, mostly from cheese and fermented foods, differ in many ways, and no study of this kind can prove the K2 did the work.
Two Dutch trials are positive, both on risk markers. In a three-year, double-blind trial in 244 healthy postmenopausal women, 180 µg a day of MK-7 not only halted the expected age-related stiffening of the arteries but modestly reversed it, measured by carotid stiffness and pulse-wave velocity.[9] The second randomized 180 people with symptomatic coronary artery disease and moderate calcium scores (50 to 400) to 360 µg a day of MK-7 or placebo for two years and analysed 167. On a coronary artery calcium scan, the median score went from 135 to 184 on MK-7 and from 145 to 214 on placebo, a statistically significant difference, though the authors say its clinical significance "remains to be determined" and a large trial with hard outcomes is needed.[10]
The Danish trials are split. In the first, 365 older men with calcified aortic valves took 720 µg a day of MK-7 plus vitamin D for two years, with no effect on valve calcification, even though dp-ucMGP fell as expected.[11] In a companion report on 304 of the men, coronary calcium did not slow significantly overall; it rose more slowly in men who started with heavy calcification (a score of 400 or more), and heart attacks, artery-opening procedures and deaths were fewer on the supplement (1.9% vs 6.7%), findings the authors call only hypothesis-generating.[12] A second Danish trial then tested that lead in 398 people with heavy coronary calcification (median age 71, 30% women). The same dose for two years slowed the build-up: the calcium score rose by an average of 196 points, against 248 on placebo, about a fifth less.[13]
Kidney disease, the obvious test case, is the weakest. People with chronic kidney disease have the worst vascular calcification and the highest dp-ucMGP. K2 reliably lowers that biomarker, but a pooled analysis of ten trials found calcification scores on scans did not change, and results on arterial stiffness are mixed.[14] A 2026 review by kidney specialists judged that K2 had not yet given reproducible benefits on calcification scans, that the somewhat more consistent, though still mixed, imaging signal comes from vitamin K1, mainly in dialysis patients given high doses, and that neither form has yet reduced heart attacks, strokes or deaths.[15]
Across trials more broadly, an earlier pooling of 14 vitamin K trials found only a borderline slowing of coronary calcium, about 17 points on the calcium-score scale, and predates both 2026 coronary trials.[16] So the biomarker moves reliably; calcification on scans moves a little in some trials and not in others; and no trial has yet been large enough to show fewer heart attacks or deaths. That gap is the honest centre of the K2 story.
Industry supply doesn't explain the split: the positive Dutch trials used MK-7 from the maker NattoPharma, but the null Danish valve trial also got its tablets free from MK-7 makers.[17] Differences in who was studied, the dose and what was measured are more plausible, though untested, explanations.
Living longer: an association, not a proof
Blood levels give a cleaner, still observational, signal. Pooling three US cohorts, adults with the lowest blood vitamin K1 had about a fifth higher death rate from any cause than those with ample levels, but no significant excess of cardiovascular events.[18] In a 15-year study of about 700 adults aged 50 to 89 in northern Italy, higher dp-ucMGP predicted more cardiovascular disease and, more strongly, death from any cause, but not heart attacks or sudden cardiac death; the link held after accounting for diet quality.[19]
Neither proves cause: low K1 could reflect a diet poorer in vegetables, and high dp-ucMGP may simply mark poorer health. No trial has shown that raising vitamin K status, or lowering dp-ucMGP, lowers mortality.
Bone: maintenance at best
The same Dutch trial in healthy postmenopausal women found that 180 µg a day of MK-7 over three years slowed the loss of bone mineral density at the lumbar spine and hip (femoral neck) against placebo.[20] But a comparable three-year trial in postmenopausal women with thinning bones (osteopenia), all taking calcium and vitamin D, found nothing: 375 µg of MK-7 switched on osteocalcin as expected, yet bone density fell equally in both groups, at every site.[21] The likeliest explanation is that MK-7 helps most in healthy bone with thin vitamin K status, and adds little once calcium and vitamin D are replete or bone is diseased.
Pooled trials point the same modest way. Trials in middle-aged and older adults show a small density gain at the lumbar spine, significant in women,[22] which shrank to non-significance in the most careful analysis when only the best-quality trials were counted, with no consistent effect at other sites.[23] Pooling eight trials (971 people), vitamin K plus vitamin D gave a small increase in total bone density compared with control or no-treatment groups, but did not test whether the pair beats vitamin D alone.[24]
K2 is a supporting nutrient for bone, not a primary driver. Heavy resistance training and impact loading do far more for bone than any micronutrient; see Bone density.
Where K2 comes from in food
K2 is scarce in Western diets, which is the real argument for a supplement.
- Natto, the Japanese fermented soybean, is in a class of its own: a 50 g serving (a little more than a standard pack) carries about 380 µg of MK-7, an order of magnitude beyond any other common food. Habitual natto eaters have more activated osteocalcin and modestly higher bone density.[25] Japanese cohorts also tie natto to lower death rates, which is observational: natto eaters differ in diet and lifestyle. See Fermented foods.
- Aged and fermented cheeses are the main Western source, and they vary widely. Aged Dutch cheeses (Gouda, Edam), Munster and Camembert are among the richest and Emmental is moderate; Brie, Gruyère, mozzarella and feta are low, and parmesan has almost none.[26] This is part of why fermented dairy looks neutral to favourable for the heart despite its saturated fat; see Dietary fats.
- Egg yolk, butter and dark poultry meat supply MK-4, but far below what nutritional studies suggest is needed to shift the proteins.
If you eat natto regularly, you don't need a K2 supplement.
Dose, and why the official numbers are lower
Dose. The positive three-year trial in healthy postmenopausal women used 180 µg a day of MK-7; 90–180 µg a day is what the rest of this site recommends alongside D3. Trials at 360–720 µg a day studied other groups with mixed results, and none has compared doses head to head, so there is no demonstrated advantage above roughly 180 µg a day for healthy adults.
The official intake. US authorities never set a full recommended allowance for vitamin K because the data were too thin; they set only an Adequate Intake (120 µg a day for men, 90 µg for women), based on what healthy people typically eat.[27] Intakes like that keep the liver's clotting factors fully active but leave roughly 20–30% of osteocalcin and MGP switched off in adults who don't supplement.[28] That gap, enough for clotting but short for the bone and vascular proteins, is the core argument for a modest MK-7 supplement. Each tissue has its own blood marker of status: PIVKA-II for clotting, uncarboxylated osteocalcin for bone and dp-ucMGP for blood vessels.
Safety, and the one caveat that matters
Safety is excellent. Natural vitamin K has no established toxicity, and the US Food and Nutrition Board set no upper limit for it because of its low potential for toxicity.[29] The supplement industry's trade association, the Council for Responsible Nutrition, reviewed more than 40 trials in 2025 and named 375 µg a day of MK-7 as the highest intake with good safety evidence (a "highest observed intake", not an upper limit), with no meaningful effect on clotting in people not taking warfarin-type drugs.[30] An earlier independent review by the US Pharmacopeia also found MK-7 supplements carry no serious health risk.[31] Synthetic vitamin K3 (menadione) is a different molecule, toxic to cells and not used in human supplements.
Warfarin and the other vitamin-K-antagonist anticoagulants are the exception. These drugs work by blocking vitamin K recycling, so supplemental K2 directly opposes them, and people taking them are advised to keep their vitamin K intake steady because sudden changes can strengthen or weaken the drug's effect.[32] The amounts involved are small. In 15 healthy volunteers given acenocoumarol (a warfarin-type drug), 10 µg a day of MK-7 lowered the international normalised ratio (INR, the standard measure of how strongly the blood is thinned) to a clinically relevant degree in at least 40% of them, and 20 µg a day did so in at least 60%; at 45 µg a day, still well below a typical supplement, the group's average INR fell by about 40%.[33] The newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) work through a different mechanism that does not involve vitamin K, so no interaction is expected.
What K2 hasn't been shown to do
The longevity claims in K2 marketing rest on observational data, animal studies, or small trials with null or marginal results.
- Telomeres. A single cross-sectional analysis linked higher dietary vitamin K to marginally longer telomeres (about 0.2 base pairs per µg).[34] Tiny, observational, and no basis for claiming K2 slows cellular ageing.
- Lifespan. K2 extends lifespan in roundworms (C. elegans) via a stress-response pathway.[35] Worm data generates hypotheses, not evidence for people.
- Brain. MK-4 is the main form of vitamin K in brain tissue, and post-mortem research links more of it to less Alzheimer pathology, but any benefit for thinking in living people is unproven.[36]
- Muscle. In a small 12-week randomized trial in 71 healthy young and older adults, 240 µg a day of MK-7 did not change strength, function, soreness or inflammation in recovery from hard resistance exercise. One author had research funding from a K2 maker.[37]
- Blood sugar. An early meta-analysis of eight randomized trials found no effect on insulin sensitivity, fasting glucose or fasting insulin.[38] Later pooled trials found a small improvement in fasting glucose and insulin resistance, though not fasting insulin,[39] somewhat larger in people with prediabetes or type 2 diabetes, from trials the authors call few and of moderate quality.[40] Not a reason to take K2.
What to actually do
- Pair MK-7 at 90–180 µg a day with vitamin D3 if you already take D3 or calcium; see Vitamin D.
- Take it with a meal that contains fat (K2 is fat-soluble), and get enough magnesium for the rest of the bone stack.
- Skip it if you eat natto regularly; a single serving carries more MK-7 than a typical 90–180 µg supplement.
- On warfarin, acenocoumarol or phenprocoumon, don't start K2 without your prescriber and INR monitoring. On a direct oral anticoagulant, no interaction is expected.
- Don't expect a longevity effect. It is a sensible adjunct for bone and arteries, not a proven extender of lifespan.
Further reading
- Knapen MHJ et al. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost 2015.[41]
- Knapen MHJ et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013.[42]
- Vossen LM et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial (VitaK-CAC). JAMA Cardiol 2026.[43]
- Diederichsen ACP et al. Vitamin K2 and D in patients with aortic valve calcification: a randomized double-blinded clinical trial (AVADEC). Circulation 2022.[44]
- Hasific S et al. Vitamin K(2) and D(3) Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial. Circulation 2026.[45]
- Rønn SH et al. The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia: a 3-year randomized, placebo-controlled trial. Osteoporos Int 2021.[46]
- Brandenburg V et al. Vitamin K and vascular calcification: from biological plausibility to clinical realism. Clin Kidney J 2026.[47]
- Shea MK et al. Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts. Am J Clin Nutr 2020.[48]
- Willeit K et al. Association of desphospho-uncarboxylated matrix Gla protein with incident cardiovascular disease and all-cause mortality: the Bruneck Study. Atherosclerosis 2022.[49]
- Mott A et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int 2019.[50]
- Theuwissen E et al. Effect of low-dose supplements of menaquinone-7 (vitamin K2 ) on the stability of oral anticoagulant treatment: dose-response relationship in healthy volunteers. J Thromb Haemost 2013.[51]
- Vermeer C. Vitamin K: the effect on health beyond coagulation — an overview. Food Nutr Res 2012.[52]
- NIH Office of Dietary Supplements. Vitamin K — Health Professional Fact Sheet.[53]